0001104659-16-159830.txt : 20161130
0001104659-16-159830.hdr.sgml : 20161130
20161130195219
ACCESSION NUMBER: 0001104659-16-159830
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161129
FILED AS OF DATE: 20161130
DATE AS OF CHANGE: 20161130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aegerion Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001338042
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 202960116
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 500-7867
MAIL ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Aegerion Pharmaceuticals Inc
DATE OF NAME CHANGE: 20050906
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chan Barbara Y
CENTRAL INDEX KEY: 0001676343
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34921
FILM NUMBER: 162026514
MAIL ADDRESS:
STREET 1: C/O AEGERION PHARMACEUTICALS INC.
STREET 2: ONE MAIN ST., SUITE 800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
a4.xml
4
X0306
4
2016-11-29
1
0001338042
Aegerion Pharmaceuticals, Inc.
AEGR
0001676343
Chan Barbara Y
C/O AEGERION PHARMACEUTICALS, INC.
ONE MAIN STREET, SUITE 800
CAMBRIDGE
MA
02142
0
1
0
0
VP, Chief Accounting Officer
Stock Option (Right to Buy)
1.58
2016-11-29
4
D
0
26000
D
2026-07-01
Common Stock
26000
0
D
25% of the shares of common stock underlying this stock option award were to vest on July 1, 2017. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through July 1, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.
Pursuant to the Agreement and Plan of Merger, dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, the option to purchase common stock of the Issuer was exchanged for an option to purchase 26,665 common shares of Novelion Therapeutics Inc. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc."
/s/ Jennifer Fitzpatrick, Attorney-in-fact
2016-11-30